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Summary 
The regulated interactions of leukocytes with vascular endothelial cells are crucial in control- 
ling leukocyte traffic between blood and  tissues.  Vascular adhesion protein-1  (VAP-1)  is  a 
novel,  human  endothelial  cell  molecule  that  mediates  tissue-selective lymphocyte binding. 
Two species  (90 and  170 kD)  of VAP-1  exist in lymphoid tissues.  Glycosidase digestions re- 
vealed that the mature 170-kD form of VAP-1 expressed on the lumenal surfaces of vessels is a 
heavily sialylated glycoprotein. The sialic  acids  are indispensable for the function of VAP-1, 
since the desialylated form of VAP-1  no longer mediates lymphocyte binding. We also show 
that L-selectin is not required for binding of activated lymphocytes to VAP-1 under conditions 
of shear stress. The 90-kD form of VAP-1 was only seen in an organ culture model, and may 
represent a monomeric or proteolytic form of the larger species. These data indicate that L-selec- 
tin  negative  lymphocytes can  bind  to  tonsillar venules  via  the  VAP-l-mediated  pathway. 
Moreover, our findings  extend the role of carbohydrate-mediated binding in lymphocyte-endo- 
thelial cell interactions beyond the known selectins.  In conclusion, VAP-1 naturally exists as a 
170-kD sialoglycoprotein that uses sialic acid residues to interact with its counter-receptors on 
lymphocytes under nonstatic conditions. 
E 
fficient functioning of the immune system requires that 
leukocytes have the  ability to  undergo rapid  changes 
from  circulating  cells  to  effector cells  in  lymphatic  and 
other  tissues  (1,  2).  Vascular  endothelium  is  strategically 
positioned for regulating  the  extravasation of leukocytes. 
At  the  blood-endothelial  cell  interface,  the  blood-borne 
leukocyte makes an initial adhesive contact with the endo- 
thelial cell.  Through a series  of steps  this interaction may 
then ultimately lead to the transmigration of the leukocyte 
between the endothelial cells into the tissue. At the molec- 
ular level, multiple sequential contacts between several en- 
dothelial  adhesion  molecules  and  their leukocyte ligands 
are required for a successful  emigration cascade (for reviews 
see references 1-7). Vascular adhesion protein 1 (VAP-1) 1 
is one of the endothelial cell molecules that mediates bind- 
ing of lymphocytes to endothelial cells (8). VAP-1  is pref- 
erentially  expressed  in  high  endothelial  venules  (HEV) 
through  which  most  lymphocyte trafficking  takes  place. 
1Abbreviations used in  this paper: ddNANA, 2,3,-dehydro, 2-deoxy-N- 
acetylneuraminic acid; HEV, high endothelial venule; PNAd, mAb 
MECA-79 defined  peripheral  lymph node addressin; VAP-1, vascular ad- 
hesion protein 1. 
VAP-1  displays a certain tissue specificity, since it is abun- 
dantly present in peripheral lymph node HEV, but consid- 
erably less is  seen in  HEV in normal muscosal lymphatic 
tissues.  However, in the setting of chronic inflammation, 
functional VAP-1  is induced/upregulated in the vessels of 
tonsil,  gut, skin, and synovium (9). mAb 1B2 against VAP-1 
inhibits lymphocyte binding to HEV, to inflamed vessels, 
and to affinity-purified VAP-1. Thus, VAP-1 supports leu- 
kocyte-endothelial cell interactions both  in  normal  lym- 
phatic tissues and at sites of inflammation. 
For functional analysis of VAP-1, a detailed knowledge 
of the biochemical structure of this molecule is required. In 
particular, elucidation of the posttranslational modifications 
of VAP-1  is important since such determinants are critical 
in conferring the recognition specificities of several adhe- 
sion molecules.  For example, mAb  MECA-79  peripheral 
lymph node-specific vascular addressins  (PNAd) (10) abso- 
lutely require sialic acid decorations and sulphate for their 
function  (11,  12).  The 50-kD  species  of these  addressins 
(glycosylation-dependent cell  adhesion  molecule-1  [Gly- 
CAM-l])  is expressed as a sialylated,  sulphated mucinlike 
molecule (13) that binds to lymphocyte L-selectin (11). It is 
striking  that  the  protein  core  of this  molecule  with  the 
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ing mammary epithelial cells and in milk, but the lack of 
sulphate  modifications renders  it incapable  of binding to 
L-selectin (14). It has also been shown that removal ofsialic 
acids or N-linked glycans from the specific ligands of P- and 
E-selectin on neutrophils abolishes binding to their respec- 
tive selectin (15). 
In the present study, we elucidate the structural modifi- 
cations of VAP-1  that are involved in lymphocyte binding 
and examine the relationship between the 170- and 90-kD 
forms of VAP-1.  We show that the mature  170-kD  form 
of VAP-1 is a heavily sialylated glycoprotein. The sialic res- 
idues are crucial for the adhesive function of VAP-1.  We 
also  show  that  L-selectin is  not  required  for  lymphocyte 
binding to VAP-1. Together, these data indicate that VAP-1 
is a novel endothehal sialoglycoprotein that mediates carbo- 
hydrate-dependent, selectin-independent lymphocyte bind- 
ing under shear stress. 
Materials and Methods 
Cells,  Tissues,  and Antibodies.  Human  tonsils  were  obtained 
from surgical operations. PBL were isolated from healthy adult 
volunteers using Ficoll gradient centrifugation.  IL-2-dependent 
T  cell lines from peripheral lymph nodes were  established and 
maintained as described (16). 
mAbs  1B2,  an inhibitory antibody against VAP-1  (8),  Leu-8 
(from  Becton  Dickinson  &  Co.,  Mountain  View,  CA),  and 
Dreg-56 (a kind gift from Professor E. Butcher, Stanford Univer- 
sity, Stanford, CA) against L-selectin (17,  18), 3G6, a nonbinding 
negative control against chicken T  cells (8), and HBl16, a bind- 
ing control against HLA ABC (19),  were used as purified Igs or 
serum-free hybridoma supernatants (all mouse lgG1). FITC-con- 
jugated sheep anti-mouse Ig was from Sigma Chemical Co.  (St. 
Louis, MO) and rabbit anti-mouse Ig and peroxidase-conjugated 
sheep anti-mouse Ig were from Dako (Glostrup, Denmark). 
Immunoblotting.  Proteins from NP-40 lysates of tonsil stromal 
elements (150  mM  NaC1,  10  mM  Tris-base, pH  7.2,  1.5  mM 
MgC12, 1% NP-40,  I% Aprotinin, and 1 mM PMSF) were used 
as the source of VAP-1 antigen. The lysate supernatants were de- 
pleted of Igs by rocking with protein G-Sepharose beads (Phar- 
macia LKB Biotechnology, Piscataway, NJ) for 2 h at room tem- 
perature  and  then  discarding the  beads.  Aliquots  of the  lysate 
were mixed with equal volumes of Laemmli's sample buffer with 
or without reduction (5% 2-ME). Samples were then subjected to 
gentle heating (20 rain at 37~  or boiling (5 min at 100~  and 
loaded on 5-12.5% SDS-PAGE gels. The resolved proteins were 
transferred onto nitrocellulose sheets (Hybond-ECL; Amersham 
International, Amersham, Bucks,  UK) by Hoefer electroblotter. 
Nitrocellulose strips  were  then  developed  using  an  enhanced 
chemiluminescence detection  kit  for  Western blotting  (Amer- 
sham International) according to the manufacturer's recommen- 
dations.  Briefly, blocking was  done  with  PBS  containing  10% 
nonfat milk powder and 0.3% Tween 20 for 1 h, and the primary 
antibodies were used at 2 I~g/ml. 
Metabolic Labeling.  Small tonsil cubes were subjected to meta- 
bolic  labeling in  an  in  vitro  organ  culture  as  described  (20). 
Briefly, ~100  mg tissue/well was  starved and labeled with 0.5 
mCi/ml [3SS]methionine/[3SS]cysteine  (Translabel; ICN Biomed- 
icals, Inc., Costa Mesa, CA) for 4 h. After lysis and four rounds of 
preclearing, the lysates were immunoprecipitated for 4 h  at 4~ 
with 15 Ixl aliquots of protein A beads armed with mAb 1B2 or 
3G6. The beads were then washed, and the antigens were eluted 
with Laemmli's sample buffer containing 5% 2-ME, and resolved 
in 5-12.5% SDS-PAGE. After electrophoresis, the gels were fixed, 
enhanced, dried, and subjected to autoradiography at -70~ 
Glycosidase Digestions  and Lectin Blotting.  For glycosidase treat- 
ments, tonsil stroma were lysed in different buffers without pro- 
tease inhibitors: (a) 50 mM sodium acetate, pH 5.5, containing 1% 
NP-40  (acetate lysate); (b) PBS containing 1% NP-40  (PBS  ly- 
sate); and (c) 10 mM Tris-base, pH 7.2,  150 mM NaC1,  1.5 mM 
MgC12, and  1% NP-40  (Tris lysate). Insoluble material was  re- 
moved by centrifugation and supematants were depleted of Igs 
with protein G beads. The size of VAP-1 antigen was identical in 
all three lysates when analyzed in parallel lanes in the same gel. 
For sialidase treatments, 0.2-25 mU  ￿88  cholerae neurarninidase 
(Behringwerke AG, Marburg, Germany), 5 mU  Clostridium  per- 
fringens,  and 5 mU Arthrobacter ureafaciens (Boehringer Mannheim, 
Mannheim, Germany) were added to 50 I.tl acetate lysate for 2 h 
at 37~  and 10 mU Newcastle disease virus neuraminidase (Gen- 
zyme Corp., Cambridge, MA) for 1 and 4 h. To digest glycopro- 
teins with O-glycanase, 50 ILl PBS lysate was first treated with  V. 
cholerae sialidase (this enzyme caused a similar change in the size of 
VAP-1 when used to digest acetate or PBS lysates) and then in- 
cubated with 16 mU recombinant endo-~x-N-acetylgalactosamini- 
dase (O-glycanase; Genzyme Corp.) overnight at 37~  N-glyca- 
nase treatment was performed overnight at 37~  using Tris-lysate 
supplemented with 0.5% SDS and 5 mM EDTA or PBS lysate to 
which  1.2  U  peptide/N-glycosidase F  (Genzyme  Corp.)  was 
added  (with  similar results).  Alternatively, PBS  lysate was  first 
subjected to neuraminidase treatment and then to overnight di- 
gestion with  N-glycanase.  For sequential  digestion of a  single 
sample with both N- and O-glycanase, 50 ILl PBS lysate was first 
treated overnight with N-glycanase, then  for  1 h  with sialidase, 
and and finally overnight with O-glycanase. For Pasteurella hemolyt- 
ica  O-sialoglycoprotein endopeptidase  (Cedarlane  Laboratories 
Ltd., Hornby, ON,  Canada) treatment, 2 or 20 b~l enzyme was 
added to PBS lysate for 1-4 h at 37~  Almond meal o~-fucosidase 
(Genzyme Corp.) and o~l,3/4-r-fucosidase from Streptomyces  sp. 
142  (Takara Biomedicals, Shiga, Japan) were used to digest ace- 
tate lysate and acetate lysate preincubated with sialidase  (10  ~U 
fucosidase, overnight at 37~ 
To study the specificity of the enzymatic treatments, 5 mU  V. 
cholerae  sialidase  and  10  btl  O-sialoglycoprotease were  prem- 
cubated with different amounts of a sialidase inhibitor 2,3-dehy- 
dro-2-deoxy-N-acetylneuraminic  acid (ddNANA; also known as 
2,3-dehydro-2,3-dideoxy-N-acetylneruaminic acid;  Boehringer 
Mannheim)  for 30  rain  at 37~  before adding the  Ig-depleted 
tonsil lysate into  the  reaction mixture. Boiled (5  min  at 95~ 
sialidase  and  O-sialoglycoprotease, and  an  irrelevant  enzyme, 
j3-galactosidase  (from Diplococcus pneumoniae,  reported to lack all 
detectable sialidase and protease activity; Boehringer Mannheim; 
2.5 mU enzyme for 25 ~1 lysate, 3 h at 37~  were used to digest 
tonsillar lysate. 
[3SS]Methionine/[3SS]cysteine-labeled VAP-1  immunocom- 
plexes were  treated with 0.1  U  neuraminidase from  V.  cholerae 
(Calbiochem-Novabiochem Corp., San Diego, CA) at 37~  for 
4 h.  The enzyme was removed by washing twice in PBS, 4 mU 
O-glycanase was added, and the incubation was continued over- 
night at 37~  Samples were then subjected to gel electrophoresis 
and enhancement as described above. 
For  lectin  blotting,  tonsil  lysates  (Tris-lysate  supplemented 
with 2 mM CaC12 and 2 mM MnC12) were depleted of Ig with 
protein G. Lectins (specificity, as stated by the manufacturers, is 
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[et-D-mannose,  C~-D-Glc],  Lens  culinaris [Ot-D-mannose],  Helix 
pomatia  [D-GalNAc],  Ulex  europaeus I  [I.-fucose],  wheat  germ 
agglutinin  [D-GlcNA2,  NeuNAc],  Bandeiraea  simplicifolia  II 
[D-GlcNAc], Artocarpus integrifolia [O-linked glycans]) were pur- 
chased from Sigma Chemical Co.  Succinylated wheat germ ag- 
glutinin  (D-GlcNAc)  and  elderberry  bark  lectin  (oLNeuNAc 
[2-6/2-3]D-Gal/GalNAc)  were  from  Vector  Laboratories,  Inc. 
(Burlingame, CA). Agarose beads on which human IgG had been 
immobilized (Sigma Chemical Co.) were used as controls. Beads 
were washed three times with lysis buffer; 50 p,1 aliquots of tonsil 
lysate were then mixed with 50 btl lectin beads and rocked for 3 h 
at room temperature. Thereafter, the supernatants were subjected 
to a second round of preclearing with fresh lectin beads.  Finally, 
supernatants were mixed with LaemmJi's sample buffer and ana- 
lyzed by immunoblotting. 
Immunostainings and FA CS  ~ Analyses.  Immunoperoxidase stain- 
ings of acetone-fixed frozen  sections were  done  exactly  as  de- 
scribed earlier (8). Lymphoid cells were stained for immunofluo- 
rescence  and  analyzed  using  a  FACScan  |  cytometer  (Becton 
Dickinson & Co.) as described earlier (16). 
HEV-bindingAssay.  The  in  vitro  frozen  section  assay  was 
conducted as described earlier (21).  In brief, 8-bLm frozen sections 
from tonsil were preincubated with mAbs (100 ~g/rnl diluted in 
RPMI 1640 containing 10% FCS and 10 mM Hepes) for 30 rain 
at  7~  under constant rotation  on  an orbital shaker  (60  rpm). 
Thereafter, 3  ￿  106 PBL in the same medium were added to tis- 
sue sections and incubation continued for another 30 rain under 
rotation. The nonadherent cells were gently tilted off, and the ad- 
herent  cells  were  fixed  in  1%  glutaraldehyde.  PBL  binding to 
HEV was counted from coded samples under dark-field illumina- 
tion. At least 120 HEV per sample were counted. The number of 
cells adherent to HEV in the presence of the negative control de- 
fines  100%  adherence.  IL-2-driven T  cells  were  preincubated 
with  mAbs Dreg-56  and  3G6,  and  thereafter  their binding to 
HEV was analyzed similarly. 
For evaluating the role of sialic acids of VAP-1 in lymphocyte 
binding to  HEV,  the  target  tissue was  pretreated  with  glycosi- 
dases.  Neuraminidase treatment was performed by incubating the 
frozen sections with  5  mU  V.  cholerae neuraminidase (Behring- 
werke)  in 50 mM sodium acetate buffer, pH 5.5, with 100 mM 
NaC1 and 5 mM CaC12 or in PBS with 2 mM CaC12 (with similar 
results)  for 30 min in a humidified chamber at 37~  For O-sialo- 
glycoprotease  digestion,  the  sections  were  incubated with  PBS 
containing 5  p~l  enzyme for  30  min at  37~  in  a  humidified 
chamber. After digestion, the enzymes were washed away and the 
sections used for  immunohistochemical stainings or binding as- 
says. In HEV assays, the sections were preincubated with mAbs, 
and finally, PBL were added as in standard HEV assays. Control 
sections were incubated with the appropriate buffers (lacking only 
the enzymes) at the first step. 
In  another set  of control  HEV-binding assays, the  enzymes 
were (a) treated with ddNANA (5 mU sialidase plus 50 p~g inhib- 
itor,  10  p~l  O-sialoglycoprotease  plus  50  p~g  inhibitor);  or  (b) 
boiled, adjusted to  100  I.tl with PBS,  and used to  predigest the 
target tissue. Other control sections were preincubated with 2.5 
mU [3-galactosidase. 
Results 
The  170-kD  Form  Is  the  Major  Immunoreactive  Species  of 
VAP-1  in  Tonsil.  Immunoblotting  of  tonsil  lysate  was 
used to determine which form ofVAP-1  (N90/180  kD) is 
the  mature,  immunoreactive molecule.  A  specific band in 
the range of 170 kD was seen (Fig.  1 A, lane 4), when the 
sample was not reduced and only mildly heated. VAP-1 re- 
activity was  destroyed  by reduction or boiling (Fig.  1  A). 
Thus,  in tonsil, the  1B2 immunoreactive epitope is in the 
170-kD  form  of the  molecule  when  the  analysis is  done 
under gentle conditions. 
To analyze further the synthesis of VAP-1 in tonsil, slices 
of human tonsil tissue were metabolically labeled and NP- 
40  soluble  proteins  were  used  for  immunoprecipitations. 
From this material, two  mAb  1B2 specific bands were  de- 
tected  (Fig.  1  B).  The size of the more prominent band at 
170 kD was similar to the mAb  1B2 reactive band seen in 
Figure 1.  The 170-kD form is the major immunoreac- 
tive  species of VAP-1.  (A)  Ig-depleted  NP-40 lysate of 
tonsil stroma were analyzed without (reduction -) or with 
(reduction +) 2-ME after boiling for 5 min at 100~  (100) 
or heating for 20 rain at 37~  (37) using SDS-PAGE and 
immunoblotting, mAb 1B2 only reacted with the 170-kD 
molecule under nonreducing conditions when boiling was 
omitted (lane 4).  3G6 is a negative control  mAb.  (/3) in 
[3SS]methionine/[3SS]cysteine--labeled  tonsil organ culture, 
mAb 1B2 specifically precipitates a major  170-kD  and a 
less prominent 90-kD form of VAP-1 (arrows). (IP) lmmu- 
noprecipitation.  Mol.  wt.  standards are indicated  on the 
left. 
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cule. The small difference between the apparent size of the 
170-kD  form  and  the  180-200-kD  form  seen  earlier by 
surface  iodination  (8)  is  due  to  the  differences in  the  gel 
systems (linear vs. gradient) and in the sample treatment. A 
less abundant 90-kD  species was also specifically immuno- 
precipitated with mAb  1B2  (Fig.  1 B). These data indicate 
that both the 170- and 90-kD forms of VAP-1 are found in 
human lymphatic tissues. 
VAP-1  Is a Sialoglycoprotein  in  Tonsil  Vessels.  To  assess 
the potential oligosaccharide modifications of VAP-1, ton- 
sil lysates were subjected to different glycosidase digestions 
before gel electrophoresis and immunoblotting (Fig. 2  A). 
Neuraminidase  (from  V.  cholerae)  treatment,  which  re- 
moves sialic acids from oligosaccharide side chains (22), in- 
creased the  apparent  molecular weight  of VAP-1  antigen 
(Fig. 2  A, lane 2).  This paradoxical change in the electro- 
phoretic mobility after sialidase treatment is consistent with 
a reduction in the net charge of the molecule due to the re- 
moval of negatively charged sialic acid residues.  Sialidases 
from C. petfringens and A.  ureafaciens  (22) produced a similar 
increase in the  apparent molecular weight of VAP-1  (data 
not shown). A  less pronounced upward shift of VAP-1 was 
detected after digestion with Newcastle disease virus neur- 
aminidase  that  specifically cleaves ot2.3  (and  tx2.8)  linked 
sialic acids (Fig. 2  A, lane 3).  Since the substrate specificity 
of Newcastle  disease  virus  neuraminidase  is  less  stringent 
during prolonged incubations  (23),  it is important to note 
that  1- and 4-h digestions with this enzyme gave identical 
results. Together,  the results from digestions with four dif- 
ferent  sialidases  indicate  that  VAP-1  contains  abundant 
sialic acid residues at least some of which are 0t2,3 linked to 
underlying oligosaccharides. 
VAP-1  was  also  susceptible to  cleavage by the  enzyme 
O-sialoglycoprotease (Fig.  2  A,  lane  4)  that  only  cleaves 
glycoproteins carrying sialylated O-linked oligosaccharides 
(23,  24).  After O-sialoglycoprotease digestion, VAP-1  was 
still detectable with mAb 1B2 and the increase in apparent 
molecular weight was slightly less than  that obtained with 
V.  cholerae  sialidase. Enzymatic digestion of sialidase-treated 
samples with  O-glycanase had only a very minor effect on 
the size of VAP-1 when compared to samples treated with 
sialidase alone (Fig. 2 A, lane 6). In contrast, neither N-gly- 
canase nor fucosidase (with or without prior desialylation) 
treatments affected the mobility of VAP-1  antigen in these 
assays.  Also, when  VAP-1  was  digested sequentially with 
N-glycanase, sialidase, and O-glycanase, the effect was sim- 
ilar to  that  of sialidase alone,  suggesting  that  O-glycanase 
did not work under these conditions (Fig. 2 A). The enzy- 
matic  activities of O-  and N-glycanase were  confirmed in 
Figure 2.  Tonsillar VAP-1 is a sialoglycoprotein.  (A) Tonsil lysates  were subjected to different enzymatic treatments before SDS-PAGE and immuno- 
blotting with mAb 1B2 and negative control (mAb 3G6). Lane I: no treatment  (acetate lysate); lane 2:  V. cholerae neuraminidase; lane 3: Newcastle dis- 
ease virus neuraminidase; lane 4: O-sialoglycoprotease;  lane 5: N-glycanase; lane 6: sialidase  treatment followed by O-glycanase; lane 7: sialidase  treat- 
ment followed by N-glycanase;  lane 8: N-glycanase treatment followed by sialidase  digestion and then O-glycanase;  lane 9: mock treatment (as in lane 8, 
but PBS was added instead of enzymes), and lane 10: fucosidase.  (B) Specificity  of the sialidase  and O-sialoglycoprotease  treatments. Same amount of ton- 
sil lysate was digested with different concentrations of V. cholerae sialidase  (sial, 25-0.2 mU), with sialidase  (5 mU) or O-sialoglycoprotease  (O-sgp, 10 btl) 
preincubated with varying amounts ofa siahdase  inhibitor ddNANA (inh), with the same enzymes alone, with the inhibitor alone, with the same amounts 
of  boiled enzymes (95~  and with 2.5 mU [3-galactosidase  (fl-gal). (-) No pretreatment. For details  of enzymatic treatments, see Materials  and Methods. 
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in mass was observed with CD44  (data not shown)  which 
is known to be modified with these sugars (25). 
The dose dependence  of sialidase  digestions was shown 
by  adding  increasing  amounts  of sialidase  to  a  constant 
amount oflysate. 0.2 mU enzyme caused only a minor in- 
crease in the apparent molecular weight ofVAP-1, whereas 
increasing amounts of sialidase  (up to 25 mU) resulted in a 
gradual upward shift in the mobility (Fig.  2  B). The speci- 
ficity of sialidase  treatment was further corroborated by us- 
ing a sialidase  inhibitor ddNANA. 7 mM of inhibitor effec- 
tively reversed the effect of sialidase,  but had no effect on 
the  electrophoretic  mobility  of VAP-1  when  used  alone 
(Fig.  2  B).  Use  of higher  concentrations  of the  inhibitor 
was  unfeasible  since  it  denatured  VAP-1  protein  (due  to 
the low pH), rendering it undetectable in immunoblotting. 
Finally,  boiled  sialidase  or  an  irrelevant  enzyme  [~-galac- 
tosidase  caused  no  shift in  the  molecular mass  of VAP-1 
when compared to nontreated samples (Fig.  2 B). Thus, the 
effect ofsialidase on VAP-1 is highly specific. 
O-sialoglycoprotease had an unusual  effect on the  elec- 
trophoretic mobility of VAP-1, since only minimal degra- 
dation  of the  VAP-1  protein  core  rather  than  complete 
fragmentation  or  marked  reduction  in  molecular  weight 
typical of most mucinlike molecules was seen.  The results 
would be compatible with the possibility that the commer- 
cial enzyme preparation might be contaminated with small 
amounts of sialidases.  Therefore,  O-sialoglycoprotease was 
preincubated  with  the  sialidase  inhibitor  ddNANA  and 
used  thereafter  to  digest  tonsil  lysate.  After this  pretreat- 
ment  O-sialoglycoprotease had no effect on the molecular 
mass of VAP-1  (Fig.  2  B).  However, the  inclusion  of the 
sialidase  inhibitor also had variable effects on the ability of 
O-sialoglycoprotease  to  degrade  known  molecules  that 
contain  mucinlike  domains  (CD34  and  GlyCAM-1  reac- 
tivities were not affected, but CD44 was only partially de- 
graded,  data not shown;  see also Discussion). As expected, 
boiled O-sialoglycoprotease had lost all its activity (Fig. 2 B). 
The  composition  of  the  VAP-1  oligosaccharide  side 
chains was further analyzed using lectins.  In particular,  the 
possibility of the  presence  of N-linked  glycans in VAP-1 
was assessed  since the  reaction conditions  for N-glycanase 
had to be compromised because of the requirements ofim- 
munoblotting.  To that  end,  tonsil lysates were precleared 
with lectins immobilized on agarose beads and the supema- 
tants  (containing  the  glycoproteins  that  were  not  recog- 
nized by the lectins) were then assayed for VAP-1  reactiv- 
ity  (Fig.  3).  Lectins  specific  for  mannose  (lens culinaris 
agglutinin  [LCA]  and Con A)  as well as those specific for 
GlcNAc  (Bandeiraca simplicifolia  [BS-II]  and  succinylated 
wheat germ agglutinin  [WGA])  and for GlcNAc or Neu- 
NAc (V4GA)  effectively absorbed all VAP-1 reactivity from 
tonsil  lysates.  Since  mannose  and  GlcNAc  residues  often 
exist in N-linked glycans in humans, these data suggest that 
VAP-1  may also contain  N-linked oligosaccharides.  Con- 
sistent  with  the  existence  of  O-linked  oligosaccharides, 
VAP-1 reactivity also disappeared by preclearing with Helix 
pomatia (HP) and Jacalin Artocarpus integrifolia (AI) lectins that 
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Figure 3.  Lectin  blotting of  VAP- 
1.  Tonsil lysates were precleared 
with lectins immobilized  on agarose 
beads, the supernatants collected  and 
analyzed by SDS-PAGE and immu- 
noblotting. Lectin preclearing  was as 
follows: lane 1: Con A; lane 2: lens 
culinaris agglutinin; lane 3:  wheat 
germ agglutinin; lane 4: succinylated 
wheat germ agglutinin; lane 5: ulex 
europaeus agglutinin I; lane 6: arto- 
carpus  integrifolia; lane  7:  helix 
pomatia agglutinin; lane  8:  elder- 
berry bark lectin; lane 9: bandeiraea 
simplicifolia II; lane 10: agarose  con- 
trol beads. Strips were probed with 
mAbs 1B2 and 3G6 (a negative con- 
trol). For details of preclearing pro- 
tocol and  specificity of lectins, see 
Materials and Methods. 
bind O-linked carbohydrates. Elderberry bark lectin (EBL), 
which recognizes sialic  acids linked to Gal or GalNac, also 
interacted  with  VAP-1  in  tonsil lysates.  In  contrast,  Ulex 
europacus aggiutinin I (UEAI) (against fucose) or control aga- 
rose  beads  coupled  with  human  Ig did  not  bind  VAP-1 
from tonsil lysates.  Together, the glycosidase digestions and 
lectin  blottings  indicate  that  VAP-1  contains  abundant 
sialic  acid decorations and that mAb 1B2 detects a protein 
rather than a sugar epitope. 
To confirm the immunoblotting results by an indepen- 
dent method, VAP-1  was also  affinity isolated from meta- 
bolically labeled tonsil fragments and treated with glycosi- 
dases. Because of technical difficulties (weak signal),  we had 
to limit the enzymes used in these experiments to sialidase 
and O-glycanase. Again, this treatment increased the size of 
VAP-1  (Fig.  4).  However, only a fraction of the  170-kD 
VAP-1  displayed altered electrophoretic mobility, indicat- 
ing that during a 4-h pulse, sialylation of all labeled VAP-1 
molecules was not  complete.  It is interesting  to  note that 
the  90-kD  form  of VAP-1  also  contained  sialic  acids/ 
O-linked  carbohydrates,  since  its  size  was  reduced  after 
neuraminidase and O-glycanase treatment. 
Sialic Acid Modifications of VAP-1  Are Required for Lym- 
phocyte Binding.  To analyze the role of sialic  acid decora- 
tions of VAP-1  in lymphocyte binding,  an in vitro frozen 
section  assay  was  employed.  Staining  of  neuraminidase 
(from  V.  cholerae) or  O-sialoglycoprotease treated sections 
revealed that  the  1B2-epitope  remained  intact  after these 
enzymatic digestions.  Enzymatic treatments were effective 
and specific since all mAb CSLEX-1  (against sialyl Lewis  ~) 
reactivity  disappeared  after  the  neuraminidase  digestion, 
and  all  CD44  reactivity  after  O-sialoglycoprotease diges- 
tion,  whereas  CSLEX-1  reactivity  remained  intact  after Figure  4.  Both the  170- and 
90-kD  forms  of  VAP-I  are 
glycoproteins.  VAP-1 isolated 
from  [3sS]  methionine/[3ss]  cys- 
teine-labeled  tonsil pieces was 
either treated with sialidase and 
O-glycanase  or  left untreated. 
Black arrows point to the origi- 
nal 170- and 90-kD forms, and 
white arrows to the altered forms 
detected  after  the  enzymatic 
treatment. Note that three times 
more digested material than un- 
treated material was loaded, and 
that all the nonspecific  bands are 
also visible in the controls, albeit 
weakly. 
O-sialoglycoprotease  and  CD44  after  sialidase  treatment, 
and buffer controls did not affect the staining pattern with 
either antibody  (Fig.  5).  The  sialidase  inhibitor  ddNANA 
completely  reversed  the  effect  of sialidase  on  CSLEX-1 
epitope  (data not shown). 
For  HEV-binding  assays,  tonsil  sections  were  treated 
with neuraminidase  or acetate buffer only, washed, and in- 
cubated with mAb 1B2 or a negative control mAb; finally, 
lymphocytes  were  applied  onto  the  sections  (Fig.  6  A). 
mAb 1B2 abrogated >50% of  lymphocyte binding to tonsil 
HEV in the buffer-treated  control samples.  In this  context 
it  should be  noted  that mAb  1B2  stains  50-70%  of tonsil 
HEV, depending on the tissue donor (8).  When the target 
tissue was pretreated with neuraminidase, lymphocyte bind- 
ing was reduced by ~50% when compared to buffer con- 
trols.  It is striking that after neuraminidase  treatment,  mAb 
1B2 had no further inhibitory effect on lymphocyte bind- 
ing to tonsil HEV, i.e., lymphocytes bound equally well to 
neuraminidase-treated  sections  incubated  with  a  negative 
control  mAb  and  mAb  1B2  (Fig.  6  A).  This  binding  is 
therefore  totally  attributable  to  the  siahdase-insensitive, 
VAP-1 negative vessels. 
The  effect of sialidase  on abrogating VAP-l-dependent 
lymphocyte binding to tonsil HEV was specific, since pre- 
treatment of the target sections with boiled enzyme or en- 
zyme preincubated with a siahdase inhibitor completely re- 
versed the  observed changes.  In the presence  of a  control 
mAb,  HBl16  lymphocytes  bound  practically  as  well  to 
HEV in  tonsil  sections  pretreated  with  boiled  sialidase  or 
with  siahdase  plus  sialidase  inhibitor  as to  control sections 
preincubated  with  PBS  only,  whereas  ~60%  fewer  lym- 
phocytes bound to HEV in sialidase-treated sections (Fig. 6 
B).  mAb  1B2  did not inhibit  PBL adherence  to  sialidase- 
treated HEV, but it did cause ~60% reduction in binding 
to  sections  treated  with  sialidase  inhibitor  plus  sialidase  or 
Figure 5.  Enzymatic digestion of tonsil sections. Frozen sections were 
treated with sialidase and O-sialoglycoprotease  and stained with CSLEX 
(against sialyl Lewis x-antigen, sLe  ~) and Hermes-1 (against CD44). (E) 
Epithelium. Bar, 20 ~m. 
with boiled sialidase.  [3-galactosidase had no effect on PBL 
binding to tonsil HEV or on the  capacity of mAb  1B2 to 
inhibit  the  adherence  (Fig.  6  B).  These  data  also  demon- 
strated  that  control  sections  treated  with  a  nonbinding 
(mAb  3G6)  or  a  binding  (anti-HLA  ABC  mAb  HB116, 
which  stains  cells  extremely  brightly)  antibody  supported 
lymphocyte adherence to a similar extent. 
O-sialoglycoprotease digestion also reduced lymphocyte 
adherence to tonsil HEV by >50%.  mAb 1B2 did not ex- 
ert  any  additional  inhibitory  effect  on  PBL  binding  after 
this  enzymatic  treatment  (Fig.  6  C).  When  O-sialoglyco- 
protease was preincubated with the sialidase  inhibitor,  65% 
of maximal  lymphocyte binding  was  observed  to  control 
mAb-treated HEV (Fig. 6 D). Furthermore,  mAb 1B2 pre- 
vented  all  of the  restored  lymphocyte binding,  indicating 
that PBL adherence had again become VAP-1  dependent. 
The reason for incomplete recovery of lymphocyte recog- 
nition of HEV treated with  O-sialoglycoprotease plus siali- 
dase  inhibitor  is  probably  the  fact  that  mucin-type  ad- 
dressins  such  as  PNAd  remain  nonfunctional  (due  to  the 
specific  action  of the  enzyme)  and  VAP-1  alone  cannot 
support adherence  of all  tonsil-binding PBL. As expected, 
boiled  O-sialoglycoprotease  was  completely  inactive  in 
these assays (Fig. 6 D). 
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Figure 6.  Sialic  acids of VAP-1 are a prerequisite for 
lymphocyte binding. Tonsil sections were treated with 
enzymes  (or  with  the  appropriate  buffers alone), 
washed and preincubated with the indicated mAbs, and 
used for HEV assays. Results are the mean +  SEM of 
four (A and C3 or two (B and D) independent experi- 
ments (different tonsils and PBL each time). Results are 
expressed as the percentage of maximal binding (bind- 
ing to the buffer-treated sections in the presence of the 
control mAb [3G6 or HB 116] defines 100% binding). 
See Materials and Methods for the details of pretreat- 
ments of the target tissue. (sial inh) ddNANA,  (O-sgp) 
O-sialoglycoprotease. 
Thus,  removal of siahc acids dramatically alters the  ca- 
pacity of tonsil venules to  bind lymphocytes. Specifically, 
the desialylated form of VAP-1 can no longer mediate lym- 
phocyte  binding,  although  it  is  still  recognized by  mAb 
1B2.  These  results suggest that  both  sialic acids and  1B2- 
epitope contribute to the ligand binding site ofVAP-1. 
The  Lymphocyte  Ligand  of  VAP-1  Is  a  Non-L-Selectin 
Molecule.  Siahc acid-dependent binding of PNAd to lym- 
phocytes has been shown to be mediated by L-selectin on 
lymphocytes (26). Therefore, we next wished to determine 
whether L-selectin is also the counter-receptor of VAP-1. 
To  that  end we took advantage  of an  IL-2-propagated T 
cell hne that retains its capacity to bind to peripheral lymph 
node type HEV  (16).  This cell hne expresses no L-selectin 
(Fig. 7 A). However, it binds to HEV  1.4 times better than 
L-selectin positive PBL under nonstatic conditions (Fig. 7 
B).  Pretreatment  of the  tonsil sections with mAb  1B2  in- 
hibited 47% of HEV binding of this L-selectin negative cell 
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line when  compared to  the  noninhibitot  3,  control  (Fig. 7 
C).  As expected, a  function-blocking anti-L-selectin mAb 
had no  effect on the binding of these cells to tonsil HEV. 
Similar results were obtained when a binding control mAb 
against HLA ABC was used (Fig. 7 D). The binding of the 
IL-2-driven T  cell line to VAP-1  was  also sialic acid de- 
pendent (data not shown). These data directly demonstrate 
that VAP-1  defines a novel non-L-selectin-dependent ad- 
hesion pathway that mediates lymphocyte binding to HEV 
under shear stress. 
Discussion 
In the present study we have shown that intact VAP-1 is 
a  170-kD sialoglycoprotein in vivo. The sialic acid residues 
are indispensable for the function of VAP-1, since desialy- 
lated VAP-1  does not support lymphocyte binding. More- 
over, VAP-1 does not use L-selectin as its counter-receptor A 
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Figure  7.  VAP-I mediates L-selectin in- 
dependent binding oflymphocytes to HEV. 
(A) The IL-2-driven T cell line was stained 
with  Leu-8  (against L-selectin), and with  a 
negative  control  (3G6). Note  that  these 
cells completely lack all surface L-selectin. 
L-selectin  expression on  freshly isolated 
PBL is shown for comparison. Mean fluo- 
rescence intensities are shown in the upper 
right comers. (/3) Relative HEV-binding ef- 
ficiency of the IL-2~zlriven T celt line and 
PBL.  (C)  Tonsil  sections were  pretreated 
with mAb 1B2, Dreg-56 (a functional anti- 
L-selectin mAb), or 3G6, and standard HEV 
assays with the T cell line were performed. 
(D) Similar frozen section assays as in  (C) 
were performed but a binding control anti- 
body (HB 116against HLA ABC) was used. 
Results in  B-D are the  mean  -+  SEM  of 
two  independent  experiments and are ex- 
pressed as a percentage of maximal binding 
(binding in the presence of a control mAb). 
on lymphocytes. These findings extend the role of carbo- 
hydrate-mediated lymphocyte-endothelial interactions be- 
yond the known selectins. Thus,  VAP-1 provides a novel, 
sialic acid-dependent pathway by which lymphocytes ad- 
here to the endothelium under nonstatic conditions using a 
non-L-selectin ligand. 
The 170-kD form of VAP-1 is a heavily sialylated glyco- 
protein in tonsil. VAP-1  was susceptible to three different 
neuraminidases isolated from  V. cholerae, C. petfringens,  and 
A.  ureafaciens which  all have  a  broad  substrate  specificity 
against terminal sialic acids linked by one  of the  common 
glycosidic linkages  (cx2,3,  ~2,6,  or c~2,8)  to  the  oligosac- 
charide  core  (22).  Newcastle  disease virus  neuraminidase 
which  specifically cleaves sialic acids linked by oL2,3 (and 
o~2,8) linkages to the underlying oligosaccharide core (27), 
also cleaved sialic acids from VAP-1. However, Newcastle 
disease  virus  neuraminidase  caused  less  pronounced  in- 
crease in the apparent molecular weight of VAP-1 than the 
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other neuraminidases.  Thus,  some,  but not  all, sialic acids 
in VAP-1 are ot2,3 linked, and the rest are most hkely in an 
c~2,6  linkage since the oL2,8 linkage is unusual in naturally 
occurring glycoproteins (28).  The effects of sialidase diges- 
tions were specific since they were dose dependent, readily 
reversed by a preincubation of the sialidase with a sialidase 
inhibitor,  and  not  detected  when  using  boiled  enzyme. 
The  sialylation capacity of tonsil high  endothelial cells is 
strikingly different from those of cultured endothelial cells, 
since VAP-1 found at low levels in certain cultured endo- 
thelial cell lines completely lacks all sialic acids and is solely 
intracytoplasmic (20).  Thus,  the  endothelial cell type-spe- 
cific  differences  in  posttranslational  modification  capacity 
critically affect proper surface location and function  of ad- 
hesion molecules. 
O-sialoglycoprotease, a  novel  metalloprotease  from  P. 
hemolytica, cleaves only proteins containing at least two ad- 
jacent  (or closely spaced)  O-linked sialylated oligosaccha- 
t  Is an Endothelial Cell Sialoglycoprotein ride side chains (i.e., mucinlike domains (23, 24)). Suscep- 
tibility of VAP-1 to O-sialoglycoprotease therefore initially 
suggested that sialic acids  in VAP-1  would be attached to 
O-linked  oligosaccharide  chains  and  that  VAP-1  would 
have  certain mucinlike  characteristics.  The fact that  after 
this endopeptidase treatment mAb  1B2 reactivity remains 
intact and that the apparent size  of VAP-1  is only slightly 
smaller than with sialidase  treatment is,  however, atypical 
of proteins containing mucinlike domains  (such as CD44, 
CD34,  and GlyCAM-1)  that are completely degraded by 
O-sialoglycoprotease. Nevertheless,  this  enzyme does  not 
destroy the antibody reactivity of all mucins. CD45, for ex- 
ample,  which  is  known  to  carry the  sialylated  O-linked 
glycans at the very NH2-terminal end of the molecule, is 
still detectable after O-sialoglycoprotease treatment and its 
apparent  molecular mass  undergoes  only a  slight  change 
(24,  and  our unpublished  observations). After preincuba- 
tion with ddNANA, which effectively inhibited the func- 
tion of V. cholerae sialidase,  O-sialoglycoprotease no longer 
altered the molecular weight of VAP-1.  These data favor 
the idea that the  observed effects of O-sialoglycoprotease 
on VAP-1  can be  caused by sialidase  contaminants.  This 
interpretation is,  however,  complicated by two  observa- 
tions.  (a)  O-sialoglycoprotease did not  destroy sialyl-Lewis  x 
on  tissue  sections,  whereas  the  CSLEX-1  epitope  was 
readily abolished by sialidase treatment. Therefore, O-sialo- 
glycoprotease preparations  are  unlikely  to  contain  major 
sialidase  contaminants,  and yet the effect of O-sialoglyco- 
protease  on  the  electrophoretic mobility  of VAP-1  was 
equal to that of 1 mU sialidase.  (b) ddNANA is known to 
also  inhibit  O-sialoglycoprotease.  10 mM  of inhibitor has 
little effect on the susceptibility of glycoprotein A  (a model 
substrate for O-sialoglycoprotease) to this enzyme, but 20 
mM causes  100% inhibition (Professor Alan Mellors, per- 
sonal communication); 2 mM sialidase inhibitor already af- 
fected the sensitivity of CD44 to O-sialoglycoprotease. The 
relative sensitivity of different target molecules to sialidases 
and O-sialoglycoprotease is variable, making generalization 
of the  results  from  sialidase  inhibitor  studies  impossible. 
Thus, we  cannot yet conclusively determine the  cause of 
the observed mobility shifts  of VAP-1  after O-sialoglyco- 
protease treatment.  It is possible that:  (a) VAP-1  contains 
only one or a few clusters of sialylated O-linked oligosac- 
charides that occur terminally in the protein core; or (b) all 
the  effects of O-sialoglycoprotease on VAP-1  are merely 
due to the low-level sialidase contamination in the enzyme 
preparations. 
Enzymatic incubation with  N-glycanase resulted in  no 
change  in  size  of VAP-1.  However,  since  the  detection 
method was based on immunoblotting, we could not use 
ideal digestion conditions for N-glycanase. Therefore, sev- 
eral lectins recognizing sugars  common in N-linked struc- 
tures were analyzed for their ability to bind VAP-1. It was 
evident that all lectins that bound mannose or GlcNAc de- 
pleted VAP-1  from tonsil lysates,  suggesting  that VAP-1 
also  contains N-linked glycans.  However, we cannot for- 
mally exclude the  possibility that VAP-1  could be  com- 
plexed to some other N-linked protein in tonsil lysate that 
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would then indirectly result in the disappearance of  VAP-1 
after lectin preclearing.  Moreover,  it  is  also  known  that 
mannose and GIcNAc can exist in O-linked oligosaccha- 
rides, and that mannose is the linkage sugar of glycophos- 
phoinositol lipid anchors. Taken together, the biochemical 
analyses  and lectin blotting showed that VAP-1  is a large 
glycoprotein carrying abundant  sialic  acid  decorations on 
O-linked  oligosaccharides  and,  likely,  also  N-linked  oli- 
gosaccharide side chains. 
In the present study, the 90-kD form of VAP-1 was de- 
tected  by  metabolic  labeling  in  a  tonsil  organ  culture 
model, and in previous studies we have also seen it in sur- 
face iodination of tonsil tissue fragments (8). This species of 
VAP-1  also  appears to be sialylated/O-glycosylated,  since 
its  molecular mass  is  reduced after sequential  neuramini- 
dase/O-glycanase treatments. The 90-kD form was not seen 
in  immunoblotting.  Thus,  it may represent a  proteolytic 
degradation product of the larger molecule that loses  the 
mAb 1B2 epitope. Alternatively, if the larger form of VAP-1 
is  a  dimer  that  is  only  partially  reduced  by  2-ME,  the 
90-kD could then be the monomeric form which lacks the 
conformation-sensitive mAb 1B2 epitope. 
The function of VAP-1 is critically dependent on proper 
sialylation.  In  HEV  assays removal  of sialic  acids  from 
VAP-1  completely abolished its  capacity to mediate lym- 
phocyte binding to tonsil vessels. In mouse, sialidase treat- 
ment has been shown to reduce lymphocyte binding to pe- 
ripheral  lymph  nodes  by  90%,  to  mesenterial  nodes  by 
50%,  and to have no effect on binding to mucosal HEV 
(29).  Our results extend these  earlier observations on the 
critical importance of sialic acids in lymphocyte binding to 
a human system. Tonsil is structurally similar to mesenteric 
nodes in the sense that it is a mixed type lymphoid organ 
containing both peripheral lymph node type HEV and mu- 
cosal  type HEV. Therefore, the ~50% inhibition in lym- 
phocyte binding after sialidase treatment alone is consistent 
with  the  abrogation of cell adherence to  desialylated pe- 
ripheral lymph node type HEV but not to those ofmucosal 
type. Since VAP-1 is expressed in peripheral type HEV but 
not significantly in normal mucosal HEV (8), it is obvious 
that mAb  1B2 against  this molecule only inhibits lympho- 
cyte binding to the VAP-1 positive subpopulation of tonsil 
HEV (i.e., gives a 50-70% inhibition). We show that both 
sialidase  and  O-sialoglycoprotease  treatment  completely 
destroy the adhesive pathway that can be inhibited by mAb 
1B2. In other words, after desialylation no functionally in- 
tact VAP-1 remains in the tissue sections that could support 
lymphocyte adherence in  the presence of a control mAb 
but not in the presence ofmAb 1B2. The effects ofsialidase 
were specific, since pretreatment of the  target tissue  with 
boiled sialidase,  sialidase  preincubated with  a sialidase  in- 
hibitor, or a nonsialic acid modifying enzyme 13-galactosidase 
did not  destroy the  VAP-l-dependent  adhesion.  Hence, 
VAP-1 (together with PNAd) is a principal neuraminidase- 
sensitive molecule that mediates lymphocyte binding to pe- 
ripheral lymph node type venules under nonstatic condi- 
tions. Although we currently cannot unambiguously define 
the  type of sialylated  oligosaccharide in VAP-1,  there are antecedents  for  both  O-linked  (endothelial  sialomucins 
GlyCAM-1,  MAdCAM-1,  and  PSGL-1)  and  N-linked 
(ESL-1)  ot2,3-sialic  acid-dependent  adhesion  during  the 
initial step of leukocyte-endothelial  cell recognition  (30). 
VAP-1 was initially judged to be different from all other 
known endothelial  adhesion molecules mediating lympho- 
cyte  binding  based  on  its  expression  pattern,  molecular 
weight,  function,  and  a  unique  NH2-terminal  sequence. 
Although  the  reported  NH2-terminal  sequence  (8)  comes 
from  a  coprecipitating  mouse  cyclophilin-C-associated 
protein  via  a  specific  mimotypic  interaction  (the  mouse 
protein binds to m_Ab 1B2 during antibody synthesis in hy- 
bridoma  ceils;  Salmi  M.,  D.  Smith,  P.  Bono,  and  S. Jal- 
kanen, manuscript submitted for publication), all other pre- 
vious and present data unambiguously show that VAP-1  is 
a  unique  human  endothelial  molecule.  Specifically, PNAd 
and VAP-1  are differentially  expressed in tonsil  HEV  and 
are differentially sensitive to O-sialoglycoprotease digestion. 
In particular, we have ruled out the identity of VAP-1 with 
the  170-180-kD  species of human  PNAd  (26)  by enzyme 
immunoassay  (EIA)  which  shows  that  the  molecules  de- 
tected by mAbs 1B2 and MECA-79  are distinct  (8). 
L-selectin  negative  IL-2-activated T  cells can adhere  to 
peripheral lymph node type HEV using VAP-1 under shear 
stress. In more general terms, when these experiments were 
performed,  VAP-1  presented  the  first molecularly  defined 
pathway that bypasses the selectin-carbohydrate  interaction 
in the first step of lymphocyte-endothelial  cell interactions. 
[During the revision of this paper, a couple of reports on an 
cx4-dependent  rolling  of leukocytes  on  mucosa-associated 
endothelium  have  been  published  (31,  32).  However, 
VAP-1  is not an ec4-figand (our unpublished  results)]. Two 
alternative  but  not  mutually  exclusive possibilities  exist to 
integrate  VAP-1  into  the  multistep  paradigm  of lympho- 
cyte-endothelial  cell binding.  (a)  Certain  lymphocytes can 
use  VAP-1  and  others  PNAd  to  make  the  first  contacts 
with  the  vascular  lining  in  peripheral  lymph  nodes.  (b) 
PNAd  and VAP-1  can act sequentially  during  the  cascade. 
In this  case,  initial  contacts  can be accounted  for by lym- 
phocyte  L-selectin  binding  to  PNAd  which  then  could 
lead  to  progression  to  the  stage  where  non-L-selectin 
ligands  make  additional  contacts  to  endothelial  VAP-1. 
Clearly,  at least activated L-selectin  negative  cells  can  cir- 
cumvent  the  PNAd-mediated  phase  of adhesion  and  al- 
ready  initially  rely  on  VAP-1.  In  either  case,  VAP-1  in- 
creases  the  possibilities  for  regulating  the  diversity  and 
specificity of lymphocyte-endothelial  cell interactions. 
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